Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03272165 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03272165 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 50 participants.
The verdict
NCT03272165, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Each participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks. The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG MEDI1341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-10-17 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03272165
The ClinicalTrials.gov registry entry for NCT03272165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03272165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03272165 about?
NCT03272165 is a clinical study titled "Single Ascending Dose Study of MEDI1341 in Healthy Volunteers". This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Each participant will receive a single 60 minute intravenous infusion of MEDI13...
What is the current status of trial NCT03272165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2017-10-17. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03272165?
The interventions under investigation include: Placebo (DRUG), MEDI1341 (DRUG).
Who is sponsoring clinical trial NCT03272165?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.